---
title: "Elicio Therapeutics posts AMPLIFY-7P presentation on ELI-002 7P in metastatic mKRAS pancreatic cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290828766.md"
description: "Elicio Therapeutics presented AMPLIFY-7P data for ELI-002 7P in metastatic mKRAS pancreatic cancer. The presentation highlighted three confirmed complete responses in MSS/MMR-proficient patients receiving nivolumab-based therapy, with two lasting at least nine months. These findings support prospective testing of ELI-002 7P combined with checkpoint inhibition. The company outlined a Phase 1 strategy targeting early efficacy signals within 3-6 months."
datetime: "2026-06-25T12:06:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290828766.md)
  - [en](https://longbridge.com/en/news/290828766.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290828766.md)
generator: "portal-rs"
---

# Elicio Therapeutics posts AMPLIFY-7P presentation on ELI-002 7P in metastatic mKRAS pancreatic cancer

-   Elicio Therapeutics published an AMPLIFY-7P research presentation outlining a development path for ELI-002 7P in metastatic mKRAS pancreatic cancer. \* Document highlights 3 confirmed complete radiographic and metabolic responses in metastatic PDAC patients who later received nivolumab-based therapy. \* All three patients were MSS/MMR-proficient; two complete responses lasted at least 9 months, including one ongoing response. \* Presentation frames the cases as hypothesis-generating, supporting prospective testing of ELI-002 7P with checkpoint inhibition in metastatic mKRAS PDAC. \* Company outlines a staged Phase 1 strategy aimed at early efficacy signals within 3-6 months of study start. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ELTX.US](https://longbridge.com/en/quote/ELTX.US.md)

## Related News & Research

- [Elicio opens Phase 1 neoadjuvant ELI-002 7P trial in resectable pancreatic cancer at MSK](https://longbridge.com/en/news/295403408.md)
- [Elicio Therapeutics plans Phase 1 trial of ELI-002 7P plus anti-PD-1, chemo in metastatic mKRAS pancreatic cancer](https://longbridge.com/en/news/290049573.md)
- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004](https://longbridge.com/en/news/296680419.md)
- [Granite-Integral co-leads $34 million Series D financing in Craif](https://longbridge.com/en/news/296226716.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**